Copy into your RSS Reader
Copy into your Podcast App
Cholesterol-fighter simvastatin, the generic version of Zocor, gets a clean bill of health in an update to a study dating back to '90s.
November 23, 2011 The latest update to a large study started in 1994 should go a long way toward dispelling any lingering worries that statins might increase risks of some illnesses, such as cancer. That was an early concern with the medicines, but one that hasn't been borne out.
June 9, 2011 Critics say the serious problems caused by the high dose of simvastatin, the generic name for Zocor, have been known for many years. But the FDA's warning didn't come until Wednesday. The drug is the most prescribed cholesterol-lowering medicine in the U.S. — and one of the cheapest.
The FDA says the highest approved dose of simvastatin, the generic name for the cholesterol-lowering drug Zocor, has been linked to increased risk of muscle injury.
June 8, 2011 The agency says the highest approved dose of simvastatin has been linked to an increased risk of muscle injury, a risk that is greatest during the first year of use. The FDA is telling doctors not to prescribe the 80 milligram dose to new patients.
NPR thanks our sponsors
Become an NPR sponsor